Yune-Fang Ueng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yune-Fang Ueng has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Chieh-Fu Chen
8 shared publicationsYun-Lian Lin
4 shared publicationsJong-Jing Wang
3 shared publicationsJyh-Fei Liao
Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC
3 shared publicationsChi-Chuo Shyu
Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC
2 shared publicationsF. Peter Guengerich
Department of Biochemistry and Center in Molecular Toxicology, School of Medicine, Vanderbilt University, Nashville, TN 37232, USA
2 shared publications
Latest Publications
- 1 July 2005
- Published by Elsevier in Life Sciences
- Vol. 77 (7) , 735-745
Dimemorfan N-demethylation by mouse liver microsomal cytochrome P450 enzymes
- 1 July 2005
- Published by Elsevier in Life Sciences
- Vol. 77 (7) , 735-745
Dimemorfan N-demethylation by mouse liver microsomal cytochrome P450 enzymes
- 29 July 2004
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 17 (8) , 1151-1156
Identification of the Main Human Cytochrome P450 Enzymes Involved in Safrole 1‘-Hydroxylation
Safrole is a natural plant constituent, found in sassafras oil and certain other essential oils. The carcinogenicity of safrole is mediated through 1‘-hydroxysafrole formation, followed by sulfonation to an unstable sulfate that reacts to form DNA adducts. To identify the main cytochrome P450 (P450) involved in human hepatic safrole 1‘-hydroxylation (SOH), we determined the SOH activities of human liver microsomes and Escherichia coli membranes expressing bicistronic human P450s. Human liver (n = 18) microsomal SOH activities were in the range of 3.5−16.9 nmol/min/mg protein with a mean value of 8.7 ± 0.7 nmol/min/mg protein. In human liver (n = 3) microsomes, the mean Km and Vmax values of SOH were 5.7 ± 1.2 mM and 0.14 ± 0.03 μmol/min/nmol P450, respectively. The mean intrinsic clearance (Vmax/Km) was 25.3 ± 2.3 μL/min/nmol P450. SOH was sensitive to the inhibition by a CYP2C9 inhibitor, sulfaphenazole, and CYP2E1 inhibitors, 4-methylpyrazole and diethyldithiocarbamate. The liver microsomal SOH activity showed significant correlations with tolbutamide hydroxylation (r = 0.569) and chlorzoxazone hydroxylation (r = 0.770) activities, which were the model reactions catalyzed by CYP2C9 and CYP2E1, respectively. Human CYP2C9 and CYP2E1 showed SOH activities at least 2-fold higher than the other P450s. CYP2E1 showed an intrinsic clearance 3-fold greater than CYP2C9. These results demonstrated that CYP2C9 and CYP2E1 were the main P450s involved in human hepatic SOH.
- 29 July 2004
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 17 (8) , 1151-1156
Identification of the Main Human Cytochrome P450 Enzymes Involved in Safrole 1‘-Hydroxylation
Safrole is a natural plant constituent, found in sassafras oil and certain other essential oils. The carcinogenicity of safrole is mediated through 1‘-hydroxysafrole formation, followed by sulfonation to an unstable sulfate that reacts to form DNA adducts. To identify the main cytochrome P450 (P450) involved in human hepatic safrole 1‘-hydroxylation (SOH), we determined the SOH activities of human liver microsomes and Escherichia coli membranes expressing bicistronic human P450s. Human liver (n = 18) microsomal SOH activities were in the range of 3.5−16.9 nmol/min/mg protein with a mean value of 8.7 ± 0.7 nmol/min/mg protein. In human liver (n = 3) microsomes, the mean Km and Vmax values of SOH were 5.7 ± 1.2 mM and 0.14 ± 0.03 μmol/min/nmol P450, respectively. The mean intrinsic clearance (Vmax/Km) was 25.3 ± 2.3 μL/min/nmol P450. SOH was sensitive to the inhibition by a CYP2C9 inhibitor, sulfaphenazole, and CYP2E1 inhibitors, 4-methylpyrazole and diethyldithiocarbamate. The liver microsomal SOH activity showed significant correlations with tolbutamide hydroxylation (r = 0.569) and chlorzoxazone hydroxylation (r = 0.770) activities, which were the model reactions catalyzed by CYP2C9 and CYP2E1, respectively. Human CYP2C9 and CYP2E1 showed SOH activities at least 2-fold higher than the other P450s. CYP2E1 showed an intrinsic clearance 3-fold greater than CYP2C9. These results demonstrated that CYP2C9 and CYP2E1 were the main P450s involved in human hepatic SOH.
- 1 January 2004
- Published by Elsevier in Life Sciences
- Vol. 74 (7) , 885-896
Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice
- 1 January 2004
- Published by Elsevier in Life Sciences
- Vol. 74 (7) , 885-896
Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice
- 1 June 2003
- Published by Taylor & Francis in Xenobiotica
- Vol. 33 (6) , 603-613
Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome P4501A2
1. Tanshinone IIA is the main active diterpene quinone in the herbal medicine Salvia miltiorrhiza. In untreated mouse liver microsomes, tanshinone IIA selectively inhibited 7-ethoxyresorufin O -deethylation (EROD) and 7-methoxyresorufin O -demethylation (MROD) activities without affecting the oxidation of benzo(a)pyrene, tolbutamide, N -nitrosodimethylamine and nifedipine. Tanshinone IIA was a competitive inhibitor of MROD activity with a K i of 7.2 ± 0.7 nM. 2. In 3-methylcholanthrene-treated mouse liver microsomes, tanshinone IIA and two minor tanshinones, tanshinone I and cryptotanshinone, inhibited liver microsomal MROD activity without affecting EROD and benzo(a)pyrene hydroxylation activities at the concentrations up to 1 µ M. Tanshinone IIA induced a type I binding spectrum with a spectral dissociation constant K s of 2.3 ± 0.8 µ M without cooperativity. 3. In human liver microsomes, tanshinone IIA decreased EROD and MROD activities without affecting the oxidation of benzo(a)pyrene, tolbutamide, chlorzoxazone and nifedipine. 4. In Escherichia coli membranes expressing bicistronic human CYP1A enzymes, tanshinone IIA inhibited EROD activity of CYP1A1 with an IC 50 48 times higher than that for CYP1A2. Tanshinone I and cryptotanshinone had the same IC 50 ratio (1A1/1A2) of 4. 5. The results indicate that tanshinone represents a new group of CYP1A inhibitors, and tanshinone IIA had the highest selectivity in inhibition of CYP1A2.
- 1 June 2003
- Published by Taylor & Francis in Xenobiotica
- Vol. 33 (6) , 603-613
Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome P4501A2
1. Tanshinone IIA is the main active diterpene quinone in the herbal medicine Salvia miltiorrhiza. In untreated mouse liver microsomes, tanshinone IIA selectively inhibited 7-ethoxyresorufin O -deethylation (EROD) and 7-methoxyresorufin O -demethylation (MROD) activities without affecting the oxidation of benzo(a)pyrene, tolbutamide, N -nitrosodimethylamine and nifedipine. Tanshinone IIA was a competitive inhibitor of MROD activity with a K i of 7.2 ± 0.7 nM. 2. In 3-methylcholanthrene-treated mouse liver microsomes, tanshinone IIA and two minor tanshinones, tanshinone I and cryptotanshinone, inhibited liver microsomal MROD activity without affecting EROD and benzo(a)pyrene hydroxylation activities at the concentrations up to 1 µ M. Tanshinone IIA induced a type I binding spectrum with a spectral dissociation constant K s of 2.3 ± 0.8 µ M without cooperativity. 3. In human liver microsomes, tanshinone IIA decreased EROD and MROD activities without affecting the oxidation of benzo(a)pyrene, tolbutamide, chlorzoxazone and nifedipine. 4. In Escherichia coli membranes expressing bicistronic human CYP1A enzymes, tanshinone IIA inhibited EROD activity of CYP1A1 with an IC 50 48 times higher than that for CYP1A2. Tanshinone I and cryptotanshinone had the same IC 50 ratio (1A1/1A2) of 4. 5. The results indicate that tanshinone represents a new group of CYP1A inhibitors, and tanshinone IIA had the highest selectivity in inhibition of CYP1A2.
- 1 August 2002
- Published by Elsevier in Life Sciences
- Vol. 71 (11) , 1267-1277
Modulation of drug-metabolizing enzymes by extracts of a herbal medicine Evodia rutaecarpa in C57BL/6J mice
- 1 August 2002
- Published by Elsevier in Life Sciences
- Vol. 71 (11) , 1267-1277
Modulation of drug-metabolizing enzymes by extracts of a herbal medicine Evodia rutaecarpa in C57BL/6J mice
- 1 March 2002
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (3) , 349-353
The Alkaloid Rutaecarpine Is a Selective Inhibitor of Cytochrome P450 1A in Mouse and Human Liver Microsomes
Rutaecarpine, evodiamine, and dehydroevodiamine are quinazolinocarboline alkaloids isolated from a traditional Chinese medicine, Evodia rutaecarpa. The in vitro effects of these alkaloids on cytochrome P450 (P450)-catalyzed oxidations were studied using mouse and human liver microsomes. Among these alkaloids, rutaecarpine showed the most potent and selective inhibitory effect on CYP1A-catalyzed 7-methoxyresorufin O-demethylation (MROD) and 7-ethoxyresorufin O-deethylation (EROD) activities in untreated mouse liver microsomes. The IC50 ratio of EROD to MROD was 6. For MROD activity, rutaecarpine was a noncompetitive inhibitor with aKi value of 39 ± 2 nM. In contrast, rutaecarpine had no effects on benzo[a]pyrene hydroxylation (AHH), aniline hydroxylation, and nifedipine oxidation (NFO) activities. In human liver microsomes, 1 μM rutaecarpine caused 98, 91, and 77% decreases of EROD, MROD, and phenacetinO-deethylation activities, respectively. In contrast, less than 15% inhibition of AHH, tolbutamide hydroxylation, chlorzoxazone hydroxylation, and NFO activities were observed in the presence of 1 μM rutaecarpine. To understand the selectivity of inhibition of CYP1A1 and CYP1A2, inhibitory effects of rutaecarpine were studied using liver microsomes of 3-methylcholanthrene (3-MC)-treated mice and Escherichia coli membrane expressing bicistronic human CYP1A1 and CYP1A2. Similar to the CYP1A2 inhibitor furafylline, rutaecarpine preferentially inhibited MROD more than EROD and had no effect on AHH in 3-MC-treated mouse liver microsomes. For bicistronic human P450s, the IC50 value of rutaecarpine for EROD activity of CYP1A1 was 15 times higher than the value of CYP1A2. These results indicated that rutaecarpine was a potent inhibitor of CYP1A2 in both mouse and human liver microsomes.
- 1 March 2002
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (3) , 349-353
The Alkaloid Rutaecarpine Is a Selective Inhibitor of Cytochrome P450 1A in Mouse and Human Liver Microsomes
Rutaecarpine, evodiamine, and dehydroevodiamine are quinazolinocarboline alkaloids isolated from a traditional Chinese medicine, Evodia rutaecarpa. The in vitro effects of these alkaloids on cytochrome P450 (P450)-catalyzed oxidations were studied using mouse and human liver microsomes. Among these alkaloids, rutaecarpine showed the most potent and selective inhibitory effect on CYP1A-catalyzed 7-methoxyresorufin O-demethylation (MROD) and 7-ethoxyresorufin O-deethylation (EROD) activities in untreated mouse liver microsomes. The IC50 ratio of EROD to MROD was 6. For MROD activity, rutaecarpine was a noncompetitive inhibitor with aKi value of 39 ± 2 nM. In contrast, rutaecarpine had no effects on benzo[a]pyrene hydroxylation (AHH), aniline hydroxylation, and nifedipine oxidation (NFO) activities. In human liver microsomes, 1 μM rutaecarpine caused 98, 91, and 77% decreases of EROD, MROD, and phenacetinO-deethylation activities, respectively. In contrast, less than 15% inhibition of AHH, tolbutamide hydroxylation, chlorzoxazone hydroxylation, and NFO activities were observed in the presence of 1 μM rutaecarpine. To understand the selectivity of inhibition of CYP1A1 and CYP1A2, inhibitory effects of rutaecarpine were studied using liver microsomes of 3-methylcholanthrene (3-MC)-treated mice and Escherichia coli membrane expressing bicistronic human CYP1A1 and CYP1A2. Similar to the CYP1A2 inhibitor furafylline, rutaecarpine preferentially inhibited MROD more than EROD and had no effect on AHH in 3-MC-treated mouse liver microsomes. For bicistronic human P450s, the IC50 value of rutaecarpine for EROD activity of CYP1A1 was 15 times higher than the value of CYP1A2. These results indicated that rutaecarpine was a potent inhibitor of CYP1A2 in both mouse and human liver microsomes.
- Open Access
- 1 January 2002
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 89 (3) , 267-273
Effects of Wu-chu-yu-tang and Its Component Herbs on Drug-Metabolizing Enzymes
The compound herbal medicine Wu-chu-yu-tang is used for the treatment of migraine and vomiting accompanying a cold. To assess the interactions of herb and drug metabolism, effects of Wu-chu-yu-tang on hepatic and renal cytochrome P450 (CYP), UDP-glucuronosyl transferase (UGT) and glutathione S-transferase (GST) were studied in C57BL/6J mice. Treatment of mice with 5 g/kg per day Wu-chu-yu-tang for 3 days caused 2.5-fold and 2.9-fold increases of liver microsomal 7-ethoxyresorufin O-deethylation (EROD) and 7-methoxyresorufin O-demethylation activities, respectively. However, CYP activities toward 7-ethoxycoumarin, benzphetamine, N-nitrosodimethylamine, erythromycin and nifedipine, and conjugation activities of UGT and GST were not affected. In kidney, Wu-chu-yu-tang-treatment had no effects on Cyp, UGT and GST activities. Among the four component herbs of Wu-chu-yu-tang, only Evodiae Fructus (Wu-chu-yu) extract increased EROD activity and CYP1a2 protein level. In E. Fructus, rutaecarpine, evodiamine and dehydroevodiamine are the main active alkaloids. At the doses corresponding to their contents in Wu-chu-yu-tang, rutaecarpine-treatment increased hepatic EROD activity, whereas evodiamine and dehydroevodiamine had no effects. These results demonstrated that ingestion of Wu-chu-yu-tang elevated mouse hepatic Cyp1a2 activity and protein level. E. Fructus and rutaecarpine contributed at least in part to the CYP1a2 induction by Wu-chu-yu-tang. Patients should be cautioned about the drug interaction of Wu-chu-yu-tang and CYP1A2 substrates.
- 1 January 2002
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 89 (3) , 267-273
Open AccessEffects of Wu-chu-yu-tang and Its Component Herbs on Drug-Metabolizing Enzymes
The compound herbal medicine Wu-chu-yu-tang is used for the treatment of migraine and vomiting accompanying a cold. To assess the interactions of herb and drug metabolism, effects of Wu-chu-yu-tang on hepatic and renal cytochrome P450 (CYP), UDP-glucuronosyl transferase (UGT) and glutathione S-transferase (GST) were studied in C57BL/6J mice. Treatment of mice with 5 g/kg per day Wu-chu-yu-tang for 3 days caused 2.5-fold and 2.9-fold increases of liver microsomal 7-ethoxyresorufin O-deethylation (EROD) and 7-methoxyresorufin O-demethylation activities, respectively. However, CYP activities toward 7-ethoxycoumarin, benzphetamine, N-nitrosodimethylamine, erythromycin and nifedipine, and conjugation activities of UGT and GST were not affected. In kidney, Wu-chu-yu-tang-treatment had no effects on Cyp, UGT and GST activities. Among the four component herbs of Wu-chu-yu-tang, only Evodiae Fructus (Wu-chu-yu) extract increased EROD activity and CYP1a2 protein level. In E. Fructus, rutaecarpine, evodiamine and dehydroevodiamine are the main active alkaloids. At the doses corresponding to their contents in Wu-chu-yu-tang, rutaecarpine-treatment increased hepatic EROD activity, whereas evodiamine and dehydroevodiamine had no effects. These results demonstrated that ingestion of Wu-chu-yu-tang elevated mouse hepatic Cyp1a2 activity and protein level. E. Fructus and rutaecarpine contributed at least in part to the CYP1a2 induction by Wu-chu-yu-tang. Patients should be cautioned about the drug interaction of Wu-chu-yu-tang and CYP1A2 substrates.
- 1 December 2001
- Published by Elsevier in Biochemical Pharmacology
- Vol. 62 (12) , 1653-1660
Protective effects of baicalein and wogonin against benzo[a]pyrene- and aflatoxin B1-induced genotoxicities11Abbreviations: AF, aflatoxin; AFB1, aflatoxin B1; AHH, benzo[a]pyrene hydroxylation; CYP, cytochrome P450; and AFO, aflatoxin B1 oxidation.
- 1 December 2001
- Published by Elsevier in Biochemical Pharmacology
- Vol. 62 (12) , 1653-1660
Protective effects of baicalein and wogonin against benzo[a]pyrene- and aflatoxin B1-induced genotoxicities11Abbreviations: AF, aflatoxin; AFB1, aflatoxin B1; AHH, benzo[a]pyrene hydroxylation; CYP, cytochrome P450; and AFO, aflatoxin B1 oxidation.
- 1 November 2001
- Published by Elsevier in Life Sciences
- Vol. 70 (2) , 207-217
Induction of cytochrome P450-dependent monooxygenase in mouse liver and kidney by rutaecarpine, an alkaloid of the herbal drug Evodia rutaecarpa
- 1 November 2001
- Published by Elsevier in Life Sciences
- Vol. 70 (2) , 207-217
Induction of cytochrome P450-dependent monooxygenase in mouse liver and kidney by rutaecarpine, an alkaloid of the herbal drug Evodia rutaecarpa
- 1 September 2000
- Published by Elsevier in Life Sciences
- Vol. 67 (18) , 2189-2200
Effects of baicalein and wogonin on drug-metabolizing enzymes in C57BL/6J mice
- 1 September 2000
- Published by Elsevier in Life Sciences
- Vol. 67 (18) , 2189-2200
Effects of baicalein and wogonin on drug-metabolizing enzymes in C57BL/6J mice